Ferring Holding SA

Four abstracts, including two oral and two poster presentations, highlight Ferring’s dedication and multi-focus approach to advancing fertility care PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals will present new data from four abstracts at the upcoming 2024 American Society for Reproductive Medicine (ASRM) Congress, being held October 19-23 in Denver, Colorado, and virtually. “We are pleased to share new data at this year’s ASRM Congress that provides healthcare professionals and fertility clinic staff with important research, findings and insights that they can apply in their clinical practice,” said Sasmira Lalwani, Senior Medical Director, Reproductive Medicine, Ferring Pharmaceuticals. “Our data presentations underscore our goal of advancing the science, supporting diverse family-building needs and providing educational resources for healthcare professionals because we understand there’s not a ‘one-size-fits-all’ approach to fertility care.” The four abstracts being presented by Ferring cover a wide range of timely and critical topics in reproductive medicine. Abstract Title Presentation Details - All times MDT Advancing Fertility Equity: Uplifting Black Women’s Voices to Design Culturally Responsive Support Solutions Poster #24 EMBARGOED UNTIL: October 21 10:45 – 11:00 a.m. Patterns of Utilization of Advanced Practice Providers in Reproductive Endocrinology: A 2023 National Survey Oral Presentation #184 EMBARGOED UNTIL: October 22 11:45 – 11:56 a.m. Impact of Gonadotropin Selection on Risk of Ovarian Hyperstimulation Syndrome (OHSS) in Predicted High Responders Undergoing Ovarian Stimulation: A Megaset-HR Trial Analysis Oral Presentation #154 EMBARGOED UNTIL: October 22 10:56 – 11:07 a.m. Assessing the Impact of an eLearning Platform for Educating Fertility Professionals Poster #652 EMBARGOED UNTIL: October 23 11:30 – 11:45 a.m. “For more than 50 years, Ferring has been relentless in our pursuit to help more people become parents by working to address the evolving needs within reproductive medicine,” said David Powley, Vice President, Reproductive Medicine and Operations, Ferring Pharmaceuticals. “ASRM is an important opportunity to share more about our contributions and long-standing investment in areas such as our product portfolio and pipeline, focus on expanding access to in vitro fertilization and work with healthcare professionals to help improve the patient experience and outcomes.” Along with the four data presentations, Ferring will also host an informative discussion entitled “Addressing Gaps and Reaching More Patients: Impacting Family Building Through Advocacy and Legislation” (October 21st at 10:05 a.m. MDT). The moderated panel discussion highlights the state and federal legislative, policy and health equity advances to expand access to family building care and infertility treatment. Moderator : Tim Clark, Director of Government Affairs, Ferring Panelists : Serena H. Chen, MD, Reproductive Endocrinologist, Division Director Emeritus & Director of Advocacy, CCRM NJ - IRMS Reproductive Medicine Michael A. Thomas, MD, Professor and Chair, Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine and Immediate Past President, American Society for Reproductive Medicine Sean B. Tipton, MA, Chief Advocacy & Policy Officer, American Society for Reproductive Medicine About Ferring Pharmaceuticals Ferring Pharmaceuticals is a privately-owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. In the United States, Ferring is a leader in reproductive medicine, and in areas of gastroenterology and orthopaedics. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Our company was founded in 1950 and is headquartered in Saint-Prex, Switzerland. Ferring employs more than 7,000 people worldwide and markets its medicines in over 100 countries. Ferring USA is based in Parsippany, New Jersey, and employs more than 900 employees. For more information, please visit , call 1-888-FERRING (1-888-337-7464), or connect with us on LinkedIn , and X (Twitter) . Contacts For more information, please contact: Lisa Perdomo Director, Brand Communications Ferring Pharmaceuticals +1-862-341-9820 lisa.perdomo@ferring.com

近日，海南普利制药股份有限公司（以下简称“普利制药”或“公司”）同时收到了英国药品和健康产品管理局（MHRA）、澳大利亚药物管理局（TGA）签发的特利加压素注射液的上市许可，这标志着普利制药生产的特利加压素注射液具备了在英国、澳大利亚上市销售的资格，将对公司拓展英国、澳大利亚市场带来积极影响。 普利制药的特利加压素注射液成功研发后，已相继提交了欧洲、中国、英国等多个国家和地区的仿制药上市申请。于2021年2月获得荷兰药物评价委员会的批准，于2021年6月获得德国联邦药物和医疗器械管理局的批准，于2022年8月获得国家药品监督管理局的批准。同时，公司的特利加压素注射液其他市场的注册工作正在持续推进中。 诚邀合作，欢迎垂询，国际招商：   Welcome for enquiry,cooperation   周先生：zm@hnpoly 特利加压素简介 特利加压素（Terlipressin，t-GLVP）为三甘氨酰基赖氨酸加压素，是一种新型人工合成的长效血管加压素类似物。通过与V1受体结合，收缩内脏血管平滑肌，降低门静脉压力，减少内脏血流；增加肾脏灌注和水钠排泄，对终末期肝病患者并发的食管胃静脉曲张出血、腹水和肝肾综合征提供一体化治疗。 特利加压素注射液最早于 2010 年 9 月 23 日在欧洲获批上市，上市的国家包括德国、荷兰、英国、西班牙、意大利等，上市许可持有人均为 Ferring。 普利特利加压素 国际化进程与市场情况 1 国际化进程 普利制药特利加压素注射液于2022年8月30日通过国家药监局审批，视同通过一致性评价批准上市，也是国内目前唯一获批上市的特利加压素水针剂型。普利制药国际市场也在积极布局，截止目前，普利制药的特利加压素注射液已在德国、荷兰和本次英国、澳大利亚的获批上市。除了以上已获批的国家外，普利制药在国际上的布局也在积极进展中，其中特利加压素注射液在审批中的国家包括马来西亚、波兰、俄罗斯、中国香港、巴基斯坦、新西兰、新加坡、泰国，待提交申报的国家包括巴拉圭、哥伦比亚、厄瓜多尔、秘鲁、越南、摩洛哥，沙特阿拉伯、墨西哥，全球化持续进行中。 2 全球市场情况 根据IQVIA数据，特利加压素针剂自2023年全球销售额达到约1亿美元，其中中国市场产出占比20%，全球排名第一；英国市场产出占比约6%，全球排名第四；德国市场产出占比约3%，全球排名第九，澳大利亚产出1.1%，普利已获批的五个国家特利加压素针剂整体销售额占全球超30%。 数据源于IQVIA数据库 凭借中美欧等多国的申报，普利制药为全球患者提供了更加多元化的治疗方案，同时显著提升了公司在国际制药领域的知名度与声誉。 诚邀合作，欢迎垂询，国际招商：   Welcome for enquiry,cooperation   周先生：zm@hnpoly 普利制药 海南普利制药股份有限公司1992年成立于海口，是中国医药制剂国际化先导企业和国家工信部智能制造示范企业，已被国家工信部纳入工业转型升级中国制造2025年儿童药重点项目企业。2017年在创业板上市后，短短3年已成为中国上市公司科技创新百强企业。公司从事药品国际化开拓15年以来，已获得170多个国际制剂上市许可，43款产品，产品远销世界各地。 未来，普利制药将一如既往地实施“先进高端制造, 面向国内国际”的全球战略，持续不断研发更多更好的药物；走向世界，为民族医药工业的强大持续作出贡献，让中国老百姓用上出口欧美的高品质健康品。 诚邀合作，欢迎垂询，国内招商：  GNXS@hnpoly.com    0571-89385059

Ferring Pharmaceuticals has expanded its gene therapy manufacturing capabilities with the opening of a new facility in Kuopio, Finland. The facility will produce the drug substance for Adstiladrin (nadofaragene firadenovec-vncg), a gene therapy used to treat non-muscle invasive bladder cancer (NMIBC). Adstiladrin is the first FDA- approved gene therapy for this specific type of bladder cancer, and Ferring has been actively expanding its clinical research to support its availability in global markets. The new manufacturing hub is part of Ferring's efforts to secure a stable supply chain for the therapy as bladder cancer cases continue to rise globally, now ranking as the ninth most diagnosed cancer worldwide. In addition to the new European facility, Ferring is also completing a U.S.-based manufacturing site in Parsippany, New Jersey.